Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Pancreatic Neoplasms: HELP
Peter C. Enzinger
Based on 5 articles published since 2009
(Why 5 articles?)
||||
Expertise Level
The expertise of Peter C. Enzinger ranks in the
  • Top 3.6%
  • ... of 93,766 published authors worldwide on Pancreatic Neoplasms
  • ... from 2009 through 2019
  • ... based on contributions to 5 articles on the topic.
Graphical view (beta)
Aliases Enzinger, Peter   ·   Enzinger, Peter C
Work Locations
Details
Most likely:    Harvard University Boston   Contact    
2017
  • Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA. · Florida Cancer Specialists, Tampa, FL, USA. · Vall d'Hebron University Hospital, Barcelona, Spain. · Erasme University Hospital, Brussels, Belgium. · HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain. · Departamento de Ciencias Médicas Clínicas, Universidad San Pablo CEU, Madrid, Spain. · Ramón y Cajal University Hospital, Madrid, Spain. · Massachusetts General Hospital Cancer Center, Boston, MA, USA. · Hospital Universitario Virgen de la Victoria, Málaga, Spain. · The Christie NHS Foundation Trust, Manchester, UK. · Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. · Brugge Oostende Oncologisch Centrum, Bruges, Belgium. · CIBERONC, La Paz University Hospital, Madrid, Spain. · The Royal Marsden NHS Foundation Trust, London, UK. · Dana Farber Cancer Institute, Boston, MA, USA. · University of Texas Health Science Center, San Antonio, TX, USA. · University of Colorado, Aurora, CO, USA. · Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. · Pubmed 28527133
2014
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA · Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA. · Pubmed 24821822
2012
  • Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA. · Pubmed 21800081
2009
  • Dana-Farber Cancer Institute, Boston, MA, USA. · Pubmed 19858396
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 19118063
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of all articles written by Peter C. Enzinger in 2009-2019 about Pancreatic Neoplasms:

  • A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. 2017
  • Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. 2014
  • A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. 2012
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 2009
  • O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. 2009
Show List of Full Article Records
Google Searches

Learn more about Peter C. Enzinger using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Harvard University Boston
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Harvard University Boston
2017
  • Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA. · Florida Cancer Specialists, Tampa, FL, USA. · Vall d'Hebron University Hospital, Barcelona, Spain. · Erasme University Hospital, Brussels, Belgium. · HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain. · Departamento de Ciencias Médicas Clínicas, Universidad San Pablo CEU, Madrid, Spain. · Ramón y Cajal University Hospital, Madrid, Spain. · Massachusetts General Hospital Cancer Center, Boston, MA, USA. · Hospital Universitario Virgen de la Victoria, Málaga, Spain. · The Christie NHS Foundation Trust, Manchester, UK. · Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. · Brugge Oostende Oncologisch Centrum, Bruges, Belgium. · CIBERONC, La Paz University Hospital, Madrid, Spain. · The Royal Marsden NHS Foundation Trust, London, UK. · Dana Farber Cancer Institute, Boston, MA, USA. · University of Texas Health Science Center, San Antonio, TX, USA. · University of Colorado, Aurora, CO, USA. · Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. · Pubmed 28527133
2014
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA · Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA. · Pubmed 24821822
2012
  • Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA. · Pubmed 21800081
2009
  • Dana-Farber Cancer Institute, Boston, MA, USA. · Pubmed 19858396
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. · Pubmed 19118063
Yearly article counts 00100101002
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.